What is MaRS Innovation?
MaRS Innovation functions as a specialized commercialization engine, dedicated to the identification and development of intellectual property emerging from its member institutions. The company provides a comprehensive suite of services, including early-stage financing, strategic deal-brokering, and operational guidance. By leveraging deep industry expertise, the firm matures its portfolio companies, preparing them for global market entry and long-term sustainability.
The organization's market position is defined by its ability to navigate the complexities of technology transfer. Unlike traditional venture firms, MaRS Innovation focuses on the foundational stages of company building, ensuring that research breakthroughs are not only scientifically sound but also commercially scalable. This dual focus on research integrity and market viability makes it an essential partner for both academic researchers and private sector investors seeking high-impact opportunities.
How much funding has MaRS Innovation raised?
MaRS Innovation has raised a total of $1.5M across 1 funding round:
Series A
$1.5M
Series A (2012): $1.5M with participation from OICR, Takeda Pharmaceutical Company Ltd., and Horizons Ventures
Key Investors in MaRS Innovation
OICR
The Ontario Institute for Cancer Research is a collaborative research institute that conducts and enables high-impact translational cancer research.
Takeda Pharmaceutical Company Ltd.
A global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, focusing on gastroenterology, oncology, and neuroscience.
Horizons Ventures
A venture capital firm that partners with entrepreneurs to turn startup ventures into successful companies through active involvement and equity financing.
What's next for MaRS Innovation?
Looking ahead, MaRS Innovation is poised to leverage its recent capital infusion to deepen its engagement with global strategic partners. The organization aims to scale its commercialization efforts, focusing on the expansion of its existing portfolio and the identification of new, high-growth research assets. By continuing to foster collaborative relationships with international pharmaceutical and technology leaders, the firm is well-positioned to drive further economic impact and technological advancement.
The strategic roadmap emphasizes the importance of sustained investment in the early-stage ecosystem. As the firm continues to mature its assets, the focus will likely shift toward securing follow-on financing and facilitating exit opportunities that maximize value for its member institutions and stakeholders. This disciplined approach to growth ensures that MaRS Innovation remains at the forefront of the commercialization field, consistently delivering value through innovation.
